Merck KGaA announced Wednesday that it is acquiring Mirus Bio, a startup that develops transfection reagents for viral cell and gene therapies, for $600 million.

“Combining Mirus Bio’s leading technology with our bioprocessing expertise and portfolio allows us to provide solutions for almost every step of viral vector development and manufacturing,” Merck KGaA board member Matthias Heinzel said in a statement.

Merck KGaA is sharpening its focus on regional manufacturing, saying in March that it plans to build a biologics facility in South Korea and will continue to invest there. The German drugmaker is also maintaining an emphasis on viral vector technology, CFO Helene von Roeder said during its first-quarter earnings presentation earlier this month, despite a slowdown in its CDMO business.

Merck KGaA bought the Madison, WI-based company from Gamma Biosciences, a “life sciences tools platform” company launched by the investment firm KKR in 2019. The deal is set to close in the third quarter.

Source: https://endpts.com/merck-kgaa-makes-600m-bet-to-boost-manufacturing-for-viral-vectors/
GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE